CAPTRUST Financial Advisors’s ALPS Medical Breakthroughs ETF SBIO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
– Sell
-6,066
Closed -$168K – 3679
2022
Q2
$168K Buy
6,066
+4,400
+264% +$125K ﹤0.01% 1822
2022
Q1
$56K Buy
1,666
+1,500
+904% +$52K ﹤0.01% 2706
2021
Q4
$7K Buy
166
+66
+66% +$2.94K ﹤0.01% 3924
2021
Q3
$5K Hold
100
– – ﹤0.01% 3959
2021
Q2
$5K Sell
100
-452
-82% -$21.7K ﹤0.01% 3876
2021
Q1
$28K Hold
552
– – ﹤0.01% 2797
2020
Q4
$28K Hold
552
– – ﹤0.01% 2101
2020
Q3
$23K Buy
552
+100
+22% +$4.12K ﹤0.01% 1912
2020
Q2
$19K Buy
+452
New +$17.8K ﹤0.01% 1962

Other funds holding SBIO

CAPTRUST Financial Advisors's SBIO Position: Q3 2022 in Review

CAPTRUST Financial Advisors sold out of ALPS Medical Breakthroughs ETF (SBIO) in Q3 2022, closing a stake of 6,066 shares — an estimated $168K sold.

CAPTRUST Financial Advisors first reported a position in SBIO in Q2 2020 and held it in 9 quarters. The position peaked at $168K in Q2 2022. 44 funds tracked by Wall St. Rank hold SBIO as of Q3 2022.

  • CAPTRUST Financial Advisors reported no remaining ALPS Medical Breakthroughs ETF position as of Q3 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 6,066 ALPS Medical Breakthroughs ETF shares in Q3 2022, an estimated $168K.
  • CAPTRUST Financial Advisors first reported a position in ALPS Medical Breakthroughs ETF in Q2 2020 and held it in 9 quarters.
  • CAPTRUST Financial Advisors's ALPS Medical Breakthroughs ETF position peaked at $168K in Q2 2022.
  • 44 funds tracked by Wall St. Rank held ALPS Medical Breakthroughs ETF as of Q3 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2022, filed 16 Nov 2022.